What's Fair in Device Write-Offs
Executive Summary
In recent months, the SEC has cracked down on technology companies that have attributed the bulk of their acquisition costs to IPR&D (in process research and development) write-offs so that it does not inflate future earnings. Now there are signals from the SEC that it is preparing to crack down on the share of acquisition costs, and medical product companies, particulary device firms, could be hit.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.